Pfizer Seeks Japan Nod for BA.4/5-Adapted COVID-19 Vaccine

September 13, 2022
Pfizer filed its bivalent COVID-19 vaccine tailored to the BA.4/BA.5 Omicron subvariants in Japan on September 13, a day after the company earned approval for its BA.1-based jab in the country. The new bivalent mRNA vaccine is based on the...read more